RABL2B

Across TCGA pan-cancer cohorts, RABL2B mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated RABL2B data layer compared with 21 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher RABL2B mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated RABL2B expression acts as an unfavorable survival marker.

PDAC, HNSC, and LUAD are the cancer types where RABL2B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.275	0.438	.018	6	view →
HNSC	DFS	Median	II,III,IV	0.537	0.797	.024	4	view →
LUAD	DFS	Median	II,III,IV	0.741	1.000	.038	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

RABL2B–PDAC (OS)

Open the PDAC breakdown →